Coherus Stock Price, News & Analysis

Coherus BioSciences (Nasdaq: CHRS) announced the unexpected passing of board member Alan C. Mendelson, who had been a director since January 2021. Mendelson was a prominent figure in the biotech industry, previously serving as external legal counsel since the company’s inception in 2010. CEO Denny Lanfear praised Mendelson's immense contributions to the company and the industry. Mendelson's extensive legal career included significant roles at Latham & Watkins LLP and Cooley LLP, advising multiple biotech firms. His loss is felt deeply across various sectors.

Coherus BioSciences (CHRS) announced positive results from a clinical trial evaluating its proposed UDENYCA® On-Body Injector (OBI). The trial demonstrated pharmacokinetic and pharmacodynamic bioequivalence with the current UDENYCA® pre-filled syringe. Enrolled were 189 subjects, and the study met all primary endpoints with no new safety concerns. Coherus plans to seek FDA marketing authorization in 2022 and expects a commercial launch shortly after approval, positioning itself to compete with Neulasta® Onpro®, which holds over 50% market share in pegfilgrastim delivery.

Coherus BioSciences announced positive results from the pivotal COLUMBUS-AMD trial, comparing the efficacy and safety of CHS-201 against Lucentis® in treating wet age-related macular degeneration. Results showed equivalent clinical efficacy and safety between both treatments in a cohort of 477 patients. If approved, CHS-201 could be marketed in the U.S. in late 2022, following the acceptance of its biologics license application by the FDA. The trial's primary endpoint was met, demonstrating significant visual acuity improvement for both treatments.

Coherus BioSciences (CHRS) announced that the FDA has accepted its 351(k) Biologics License Application (BLA) for CHS-201, a biosimilar of Lucentis. The FDA's target action date is set for August 2, 2022. If approved, Coherus plans to launch CHS-201 in the U.S. in the second half of 2022. The BLA was submitted by Coherus’ partner Bioeq AG, from whom they acquired U.S. commercial rights in 2019. Coherus also anticipates future launches of additional biosimilars, building on their successful biosimilar commercialization track record.

Coherus BioSciences (Nasdaq: CHRS) has announced the passing of board member Dr. Samuel Nussbaum, who served since May 2018. Dr. Nussbaum was a prominent healthcare executive and physician with significant contributions to the industry. His leadership was valued by Coherus, and CEO Denny Lanfear expressed deep gratitude for his service. Dr. Nussbaum previously held executive roles at Anthem and had a distinguished career in medicine and research, including a tenure at Harvard Medical School. His absence will be felt across the organization.

Coherus BioSciences, Inc. (Nasdaq: CHRS) announced on Sept. 24, 2021, that it granted options to purchase 229,500 shares of common stock to newly hired employees, effective Sept. 22, 2021. The options have an exercise price of $17.06, matching the closing trading price on the grant date. Among the recipients, a new Senior Vice President received options for 100,000 shares. These grants were made under the Coherus BioSciences 2016 Employment Commencement Incentive Plan, approved to attract new talent.

Coherus BioSciences (CHRS) and Junshi Biosciences announced positive interim results from the Phase 3 JUPITER-06 trial on toripalimab combined with chemotherapy for advanced esophageal squamous cell carcinoma (ESCC). The study demonstrated statistically significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to chemotherapy alone, meeting co-primary endpoints. The companies plan to submit a Biologics License Application (BLA) supplement in 2022 to expedite toripalimab's availability for ESCC patients in the U.S. Full data will be presented at the ESMO Congress on September 17, 2021.

Coherus BioSciences (Nasdaq: CHRS) and Shanghai Junshi Biosciences announced significant findings from the JUPITER-02 clinical trial, published in Nature Medicine. The Phase 3 trial demonstrated that toripalimab combined with standard chemotherapy improved progression-free survival (PFS) in patients with advanced nasopharyngeal carcinoma (NPC), showing a median PFS of 11.7 months versus 8.0 months with chemotherapy alone. While overall survival data is not yet mature, a 40% reduction in death risk was noted. A biologics license application has been submitted to the FDA for approval.

Coherus Biosciences (CHRS) and Junshi Biosciences have announced positive interim results from the Phase 3 clinical trial CHOICE-01, assessing toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC). The interim analysis showed significant improvement in progression-free survival (PFS) compared to chemotherapy alone. The data was presented at the World Conference on Lung Cancer. Further analyses are anticipated later this year, with plans for FDA discussions for a biologics license application for toripalimab in the U.S.